SCHEMBL5773449

SCHEMBL5773449

O=Cc1cn2cc(I)ccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.43
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
CCR1 P32246 1/20 0.32
PIK3CG P48736 1/20 0.31
HDAC1 Q13547 1/20 0.30
HDAC2 Q92769 1/20 0.30
ALDH1A1 P00352 2/20 0.30
SMN1; SMN2 Q16637 2/20 0.30
P2RX7 Q99572 1/20 0.30
LMNA P02545 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
MITF O75030 1/20 0.30
KDM5A P29375 1/20 0.30
KDM5C P41229 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL871995 0.79 NPC1 (0.50) APPALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL11914801 0.78 PIK3CG (0.55) APPPIK3CGALDH1A1SMN1; SMN2LMNA
SCHEMBL869867 0.78 APP (0.43) APPCCR1ALDH1A1KDM4ENPC1
SCHEMBL4784975 0.78 RAB9A (0.51) APPALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL14046264 0.78 PIK3CG (0.38) APPCCR1PIK3CGHDAC1HDAC2
SCHEMBL871327 0.76 PTGS1 (0.51) HDAC1HDAC2ALDH1A1SMN1; SMN2LMNA
SCHEMBL25045602 0.74 APP (0.49) APPDRD2DRD4DRD3PIK3CG
SCHEMBL4897330 0.74 APP (0.47) APPALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL11914803 0.74 ALDH1A3 (0.60) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL716403 0.74 KDM4E (0.50) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT APP 1/4885DRD2 1630/4885DRD4 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.